Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is bullish on the stock heading into Phase 3 Origin results in IgAN expected in Q2 as well as over the long-term with an anticipated atacicept commercial launch in 2026, the analyst tells investors in a research note. Although povetacicept has a potential market advantage with its more convenient dosing regimen, it will be challenging to demonstrate better results as atacicept has already proven to stabilize eGFR over a long period of time, Wolfe added.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics initiated with an Outperform at Wolfe Research
- 3 Best Stocks to Buy Now, 1/29/2025, According to Top Analysts
- Vera Therapeutics initiated with a Buy at Goldman Sachs
- 3 Best Stocks to Buy Now, 1/17/2025, According to Top Analysts
- Vera Therapeutics Highlights Atacicept Progress at Conference